What's Going On With Esperion Stock Tuesday? - Esperion Therapeutics (NASDAQ:ESPR)

Core Viewpoint - Esperion Therapeutics has announced a definitive agreement to acquire Corstasis Therapeutics, which is expected to enhance its product portfolio and drive revenue growth despite a bearish trend in its stock performance [1][5]. Acquisition Details - The acquisition involves an upfront cash payment of $75 million, with potential royalties and milestone payments totaling up to $180 million [3]. - The transaction is expected to close in the second quarter of 2026, with Esperion financing the acquisition through existing credit facilities and royalty monetization [4][3]. Product and Market Opportunity - Corstasis has developed Enbumyst, the first FDA-approved nasal spray diuretic for treating edema associated with congestive heart failure, targeting a market opportunity exceeding $4 billion in the U.S. [2][5]. - The integration of Enbumyst is anticipated to drive double-digit revenue growth for Esperion [5][6]. Financial Performance and Analyst Outlook - Esperion's cash and cash equivalents totaled $92.4 million as of September 30, 2025 [4]. - The company is set to report earnings on March 10, 2026, with an EPS estimate of 26 cents, up from a loss of 11 cents, and a revenue estimate of $163.31 million, up from $69.11 million [8][9]. - The stock currently carries a Buy Rating with an average price target of $6.31, with recent analyst actions indicating positive sentiment [10]. Stock Performance and Technical Analysis - Esperion's stock is trading 5.5% below its 20-day simple moving average and 12.3% below its 100-day simple moving average, indicating a bearish trend [6]. - The RSI is at 44.45, suggesting neutral territory, while the MACD indicates bearish pressure [7].